In the MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD) and ANCHOR (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD) trials, it was demonstrated that about 88% of patients treated with monthly intravitreal injections of ranibizumab had improved vision after two years [169]. This evidence concerns the gene VEGFA and choroidal neovascularization.